Maximizing Options to Advance Informed Choice for HIV Prevention
Region: Sub-Saharan Africa
Funder: U.S. Agency for International Development (USAID), U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)
Project Duration: 2021 – 2026
LVCT Health is implementing Maximizing Options to Advance Informed Choice for HIV Prevention (MOSAIC) is a five-year (2021-2026) global project funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Agency for International Development (USAID) to help adolescent girls and young women and other women* prevent HIV by accelerating introduction and scale-up of new and emerging biomedical prevention products.
MOSAIC works across multiple countries to implement user-centered research and research translation efforts to identify, understand and remove barriers to new product introduction, access and use; coordinate and provide technical assistance to global, national and subnational stakeholders to expedite product launch and scale-up; and strengthen the capacity of a wide range of local partners to perform essential functions that support the introduction of HIV prevention products.
The MOSAIC consortium is led by FHI 360 along with core partners Wits Reproductive Health and HIV Institute (Wits RHI), Pangaea Zimbabwe AIDS Trust (PZAT), LVCT Health, Jhpiego and AVAC. Local partner leadership and engagement, particularly in sub-Saharan Africa, is intrinsic to the project’s approach to expediting women’s access to new HIV prevention products. The work will also be supported by technical partners from Afton Bloom, Avenir Health, Columbia University, Mann Global Health, RTI International, the University of Pittsburgh and the University of Washington.
Working closely with product developers, MOSAIC will advance access to and uptake within a multiproduct market that includes options such as oral pre-exposure prophylaxis (oral PrEP), the dapivirine ring (also called PrEP ring) and injectable long-acting cabotegravir (CAB PrEP). Proposed countries for the consortium’s work are Kenya, South Africa, Zambia, Zimbabwe, Eswatini, Lesotho, Uganda, Namibia, and Nigeria.
*MOSAIC end users include cisgender women, transgender women, and nonbinary people and transgender men assigned female at birth; in addition, specific underrepresented groups within these end user populations include very young adolescents, sex workers, pregnant and breastfeeding individuals, those engaged in transactional sex, and individuals who use drugs.
The CATALYST Study
Catalyzing Access to New Prevention Products to Stop HIV (CATALYST) is MOSAIC’s flagship product introduction study. The study will provide and assess an enhanced service delivery package that includes oral PrEP, PrEP ring, and injectable cabotegravir. The package of products and services for PrEP will be provided to women* at PEPFAR/USAID delivery sites in Kenya, Lesotho, South Africa, Uganda, and Zimbabwe. The CATALYST study will also use quality improvement methods to refine the program and identify a core package for delivering PrEP choice.